Onconic Therapeutics' OCN-501 Named Late-Breaking Oral at ObesityWeek 2026
The US obesity society selected Onconic Therapeutics' OCN-501 abstract for an oral session; full data will be presented in Washington D.C. in November.
Onconic Therapeutics announced that the US obesity society has released the title of a Late-Breaking oral presentation abstract for ObesityWeek 2026. According to ZDNet Korea, the abstract is titled "A First-in-Class OCN-501 Preserves Skeletal Muscle During Semaglutide-Induced Weight Loss."
The OCN-501 study was accepted as an ObesityWeek 2026 Late-Breaking Abstract and selected for the "Emerging Obesity Therapies and Clinical Outcomes" oral session.
The company stated that detailed research methods, results and data will be disclosed at the US obesity society's presentation in Washington D.C. in November under the conference embargo policy.
This marks the first time an undisclosed new drug candidate from Onconic Therapeutics has been revealed since its next-generation anticancer candidate nesuparib.
Muscle Preservation in Focus
GLP-1 obesity treatments such as Wegovy and Mounjaro have been growing rapidly. Studies have reported that weight loss via GLP-1 treatments can reduce not only fat but also lean body mass and muscle mass.
Eli Lilly, the developer of Mounjaro, lists "GLP-1/incretin add-on" and "body composition improvement such as preserving or increasing lean body mass" as key BD interest areas on its Corporate Business Development page. Onconic Therapeutics has accumulated drug development experience through the commercialization of Jaycupro and the development of the anticancer drug nesuparib.
Quick answers
Where and when will the OCN-501 data be presented?
Onconic Therapeutics said the details will be disclosed during the US obesity society's presentation in Washington D.C. in November 2026, under the conference embargo policy.
What is the title of the OCN-501 abstract?
It is titled "A First-in-Class OCN-501 Preserves Skeletal Muscle During Semaglutide-Induced Weight Loss."
What session was the OCN-501 study selected for at ObesityWeek 2026?
It was selected for the "Emerging Obesity Therapies and Clinical Outcomes" oral session as a Late-Breaking Abstract.